PHASE II STUDY OF COMBINATION CHEMOTHERAPY WITH BIWEEKLY CETUXIMAB AND IRINOTECAN FOR WILD-TYPE KRAS METASTATIC COLORECTAL CANCER REFRACTORY TO IRINOTECAN, OXALIPLATIN, AND FLUOROPYRIMIDINES

被引：0
|
作者：
Yuki, S. [1 ]
Shitara, K. [2 ]
Yoshida, M. [3 ]
Takahari, D. [2 ]
Utsunomiya, S. [4 ]
Yokota, T. [2 ]
Sato, Y. [2 ]
Tajika, M. [2 ]
Muro, K. [2 ]
机构：
[1] Hokkaido Univ Hosp, Sapporo, Hokkaido 060, Japan
[2] Aichi Canc Ctr Hosp, Nagoya, Aichi 464, Japan
[3] Osaka Med Coll, Takatsuki, Osaka 569, Japan
[4] Nagoya Kyouritsu Hosp, Nagoya, Aichi, Japan
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：216 / 216
页数：1
相关论文
共 50 条
  • [1] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Shitara, Kohei
    Yuki, Satoshi
    Yoshida, Motoki
    Takahari, Daisuke
    Utsunomiya, Setsuo
    Yokota, Tomoya
    Sato, Yozo
    Inaba, Yoshitaka
    Tajika, Masahiro
    Kawai, Hiroki
    Yamaura, Hidekazu
    Kato, Mina
    Yamazaki, Kentaro
    Komatsu, Yoshito
    Muro, Kei
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (02) : 787 - 793
  • [2] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Yuki, S.
    Shitara, K.
    Yoshida, M.
    Takahari, D.
    Utsunomiya, S.
    Yokota, T.
    Sato, Y.
    Tajika, M.
    Muro, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [3] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Kohei Shitara
    Satoshi Yuki
    Motoki Yoshida
    Daisuke Takahari
    Setsuo Utsunomiya
    Tomoya Yokota
    Yozo Sato
    Yoshitaka Inaba
    Masahiro Tajika
    Hiroki Kawai
    Hidekazu Yamaura
    Mina Kato
    Kentaro Yamazaki
    Yoshito Komatsu
    Kei Muro
    Investigational New Drugs, 2012, 30 : 787 - 793
  • [4] COMBINATION CHEMOTHERAPY WITH BIWEEKLY CETUXIMAB AND IRINOTECAN FOR WILD-TYPE KRAS METASTATIC COLORECTAL CANCER, REFRACTORY TO BOTH OXALIPLATIN AND IRINOTECAN
    Barbosa, Caroline
    Sousa, Romulado
    Sabbaga, Jorge
    Cotti, Guilherme
    Saragiotto, Daniel
    Hoff, Paulo
    ANNALS OF ONCOLOGY, 2011, 22 : v103 - v103
  • [5] Phase II Study of Combination Chemotherapy with Biweekly Cetuximab and Irinotecan for Pre-treated Metastatic Colorectal Cancer Harboring Wild-type KRAS
    Shitara, Kohei
    Yokota, Tomoya
    Takahari, Daisuke
    Shibata, Takashi
    Ura, Takashi
    Komatsu, Yoshito
    Yuki, Satoshi
    Yoshida, Motoki
    Takiuchi, Hiroya
    Utsunomiya, Setsuo
    Yatabe, Yasushi
    Muro, Kei
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (07) : 699 - 701
  • [6] Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS
    Shitara, Kohei
    Yokota, Tomoya
    Takahari, Daisuke
    Shibata, Takashi
    Ura, Takashi
    Utsunomiya, Setsuo
    Inaba, Yoshitaka
    Yamaura, Hidekazu
    Sato, Yozo
    Najima, Mina
    Kawai, Hiroki
    Tajika, Masahiro
    Sawaki, Akira
    Yatabe, Yasushi
    Muro, Kei
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (04) : 688 - 693
  • [7] Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS
    Kohei Shitara
    Tomoya Yokota
    Daisuke Takahari
    Takashi Shibata
    Takashi Ura
    Setsuo Utsunomiya
    Yoshitaka Inaba
    Hidekazu Yamaura
    Yozo Sato
    Mina Najima
    Hiroki Kawai
    Masahiro Tajika
    Akira Sawaki
    Yasushi Yatabe
    Kei Muro
    Investigational New Drugs, 2011, 29 : 688 - 693
  • [8] Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS
    Hong, Yong Sang
    Kim, Hwa Jung
    Park, Seong Joon
    Kim, Kyu-Pyo
    Lee, Jae-Lyun
    Park, Jin Hong
    Kim, Jong Hoon
    Lim, Seok-Byung
    Yu, Chang Sik
    Kim, Jin Cheon
    Baek, Ji Yeon
    Kim, Sun Young
    Kim, Tae Won
    CANCER SCIENCE, 2013, 104 (04) : 473 - 480
  • [9] Multicenter Phase II Study of Cetuximab Plus Irinotecan in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin and Fluoropyrimidines
    Tahara, Makoto
    Shirao, Kuniaki
    Boku, Narikazu
    Yamaguchi, Kensei
    Komatsu, Yoshito
    Inaba, Yoshitaka
    Arai, Tatsuhiro
    Mizunuma, Nobuyuki
    Satoh, Taroh
    Takiuchi, Hiroya
    Nishina, Tomohiro
    Sakata, Yuh
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 38 (11) : 762 - 769
  • [10] A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer
    Sclafani, Francesco
    Kim, Tae Y.
    Cunningham, David
    Kim, Tae W.
    Tabernero, Josep
    Schmoll, Hans J.
    Roh, Jae K.
    Kim, Sun Y.
    Park, Young S.
    Guren, Tormod K.
    Hawkes, Eliza
    Clarke, Steven J.
    Ferry, David
    Frodin, Jan-Erik
    Ayers, Mark
    Nebozhyn, Michael
    Peckitt, Clare
    Loboda, Andrey
    Mauro, David J.
    Watkins, David J.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (12):
12345